
FOLLOWUS
1. Department of Infectious Diseases, Affiliated Hospital of Guiyang Medical College,Guizhou
2. Department of Pathophisiology, Guiyang Medical College,China
3. Department of Infectious Diseases, People’s Hospital of Guizhou Province,China
4. Department of Pharmacology, Guiyang Medical College,China
Published:2004,
Scan for full text
Xiao-xia, G., Qin, Y., Ru-jia, X. et al. Effect of Danshao Huaxian capsule on the expression of collagen I, III, and caspase-3 in hepatic fibrosis rats., Chin. J. Integr. Med. 10, 289–295 (2004). https://doi.org/10.1007/BF02836432
Geng Xiao-xia, Yang Qin, Xie Ru-jia, et al. Effect of Danshao Huaxian capsule on the expression of collagen I, III, and caspase-3 in hepatic fibrosis rats. [J]. Chinese Journal of Integrative Medicine 10(4):289-295(2004)
Xiao-xia, G., Qin, Y., Ru-jia, X. et al. Effect of Danshao Huaxian capsule on the expression of collagen I, III, and caspase-3 in hepatic fibrosis rats., Chin. J. Integr. Med. 10, 289–295 (2004). https://doi.org/10.1007/BF02836432 DOI:
Geng Xiao-xia, Yang Qin, Xie Ru-jia, et al. Effect of Danshao Huaxian capsule on the expression of collagen I, III, and caspase-3 in hepatic fibrosis rats. [J]. Chinese Journal of Integrative Medicine 10(4):289-295(2004) DOI: 10.1007/BF02836432.
Objective: To study the effect of Danshao Huaxian capsule (DSHX)
a traditional Chinese medical prescription
on the expression of collagen (Col) I
III and cysteinyl aspartate specific proteases-3 (caspase-3) in CCl4-induced hepatic fibrosis in rats. And also it is to explore the mechanism of DSHX in anti-fibrosis.Methods: Eighty male Wistar rats were randomly divided into the normal control group (A)
the model group (B)
the un-treated model group (C)
the low-dose-DSHX treated group (D) and the high-dose-DSHX treated group (E). Except those in Group A
all the other rats were made into hepatic fibrotic models by comprehensive processes including subcutaneous injecting of CCl4
and feeding them with alcoholic high-fat and low-protein diet for 8 weeks. Then the two DSHX-treated groups were treated respectively with low dose (0.5 g/kg) and high dose (1.0 g/kg) DSHX capsule by gastrogavage everyday for 8 weeks. At the end of the experiment
the liver index
levels of hyaluronic acid (HA) and alanine aminotransferase (ALT) in serum
degree of hepatic fibrosis
and urinary excretion of hydroxyproline (Hyp) were measured
and the expression of Col I
Col III and caspase-3 in liver tissues were detected respectively by immunohistochemistric technique.Results: Compared with those in Group B and C
the two DSHX treated groups showed that the liver index
levels of serum HA and ALT and severity of hepatic fibrosis were all significantly lower
the urinary excretion of Hyp was significantly higher; the Col I and Col-III expression was lower (Col I: 1.23±1.14
1.07 ±0.96 vs 4.18±2.26
3.22±1.44
P<0.01;Col III: 1.31±0.69
1.09±0.58 vs 3.04±0.62
2.23±0.58
P<0.05). At the same time
the expression of caspase-3 in Group E was fewer than Group B and C in hepatocytes (3.09±0.65 vs 9.60±2.32
8.82±1.45
P<0.01)
but it was extensively expressed in fibrous septal cells(4.52±0.87 vs 1.69±0. 23
2. 98±0. 36
P<0.01).Conclusion: DSHX capsule shows certain therapeutic effect on hepatic fibrosis in rats
and the mechanism might be related with reducing Col I and Col III deposition
inhibiting hepatocyte apoptosis and promoting fibrous septal cells (mainly the activated hepatic stellate cells) apoptosis.
Objective: To study the effect of Danshao Huaxian capsule (DSHX)
a traditional Chinese medical prescription
on the expression of collagen (Col) I
III and cysteinyl aspartate specific proteases-3 (caspase-3) in CCl4-induced hepatic fibrosis in rats. And also it is to explore the mechanism of DSHX in anti-fibrosis.Methods: Eighty male Wistar rats were randomly divided into the normal control group (A)
the model group (B)
the un-treated model group (C)
the low-dose-DSHX treated group (D) and the high-dose-DSHX treated group (E). Except those in Group A
all the other rats were made into hepatic fibrotic models by comprehensive processes including subcutaneous injecting of CCl4
and feeding them with alcoholic high-fat and low-protein diet for 8 weeks. Then the two DSHX-treated groups were treated respectively with low dose (0.5 g/kg) and high dose (1.0 g/kg) DSHX capsule by gastrogavage everyday for 8 weeks. At the end of the experiment
the liver index
levels of hyaluronic acid (HA) and alanine aminotransferase (ALT) in serum
degree of hepatic fibrosis
and urinary excretion of hydroxyproline (Hyp) were measured
and the expression of Col I
Col III and caspase-3 in liver tissues were detected respectively by immunohistochemistric technique.Results: Compared with those in Group B and C
the two DSHX treated groups showed that the liver index
levels of serum HA and ALT and severity of hepatic fibrosis were all significantly lower
the urinary excretion of Hyp was significantly higher; the Col I and Col-III expression was lower (Col I: 1.23±1.14
1.07 ±0.96 vs 4.18±2.26
3.22±1.44
P<0.01;Col III: 1.31±0.69
1.09±0.58 vs 3.04±0.62
2.23±0.58
P<0.05). At the same time
the expression of caspase-3 in Group E was fewer than Group B and C in hepatocytes (3.09±0.65 vs 9.60±2.32
8.82±1.45
P<0.01)
but it was extensively expressed in fibrous septal cells(4.52±0.87 vs 1.69±0. 23
2. 98±0. 36
P<0.01).Conclusion: DSHX capsule shows certain therapeutic effect on hepatic fibrosis in rats
and the mechanism might be related with reducing Col I and Col III deposition
inhibiting hepatocyte apoptosis and promoting fibrous septal cells (mainly the activated hepatic stellate cells) apoptosis.
Liver Fibrosiscollagencysteinyl aspartate specific proteases-3apoptosistraditional Chinese herbs
Liver Fibrosiscollagencysteinyl aspartate specific proteases-3apoptosistraditional Chinese herbs
Weng HL, Cai WM, Liu RH. Animal experiment and clinical study of effect of gamma 2 interferon on hepatic fibrosis. World J Gastroenterol 2001; 7: 42–48.
Li CX, Luo J, Li L, et al. The protective effects of Handan Ganle on CCl4-induced liver fibrosis in rats. Chin Public Health 1998; 14(9): 527–529.
Zhang HN, Li CX, Huang NH, et al. The preventive actions of traditional Chinese medicine Handan Ganle on immune liver fibrosis in rats. Guizhou Med J 2001; 25(5): 415–417.
Cheng ML, Ding YS, Luo YF, et al. The clinical research of the therapeutic effects of Handan Bituo on chronic active hepatitis. Chin J Integr Tradit West Med 1996; 16(7): 431–432.
Cheng ML, Yang CQ. The basic study and clinical research on hepatic fibrosis. Los Angeles: First Jumbo Publishing Co, 2002: 29–30.
Bissell DM. Connective tissue metabolism and hepatic fibrosis: an overview. Semin Liver Dis 1990; 10(1): iiiiv.
Oberti F, Valsesia E, Pilette C, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. J Gastroenterol 1997; 113(5): 1609–1614.
Zheng M, Cai WM, Weng HL, et al. ROC curve in evaluation of serum fibrosis index for diagnosing hepatic fibrosis. Chin J Infect Dis 2002; 20(4): 225–227.
Ding HB, Chen YP, Feng XR, et al. Correlation analysis between liver fibrosis stage and serum liver fibrosis markers in patients with chronic hepatitis B. Chin J Hepatol 2001; 9(2): 78–80.
Gao CF, Ye WM, Xu LL, et al. Application study of serum markers in the diagnosis of fibrotic liver disease. Chin J Lab Med 2001; 24(2): 91–93.
Schuppan D. Structure of the extracellular matrix in normal and fibrotic liver: collagens and glycoproteins. Semin Liver Dis 1990; 10(1): 1–10.
Patel T, Gores GJ. Apoptosis and hepatobiliary disease. Hepatol 1995; 21(6): 1725–1741.
Lu P, Luo HS, Yu BP. Hepatocellular apoptosis and its apoptosis-regulating gene in rat liver fibrosis model. World J Gastroenterol 2001; 9(2): 165–169.
Zhang HL, Wang WL, Hu LZ. Detection of the mutation of p53 and K-ras genes and their expression products. J Fourth Milit Med Univ 1999; 20(9): 769–771.
Nagata S. Apoptosis by death factor. Cell 1997; 88(3): 355–365.
Schulz JB, Weller M, Moskowitz MA. Caspases as treatment targets in stroke and neurodegenerative diseases. Ann Neurol 1999; 45(4): 421–429.
Wolf BB, Schuler M, Echeverri F, et al. Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/inhibitor of caspase-activated DNase inactivation. J Biol Chem 1999; 274 (43): 30651–30656.
Pawlowski J, Kraft AS. Bax-induced apoptosis. Proc Natl Acad Sci USA 2000; 97(2): 529–531.
Tao J, Cai WM, Lu LW, et al. Expression of Bcl-2 and Bax proteins in rat liver fibrosis model and the role of IFN-γ. Chin J Hepatol 2003; 11(11): 669–672.
Issa R, Williams E, Trim N, et al. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut 2001; 48 (4): 548–557.
Jiang CM, Liu C, Liu P. The developing researches of the HSC during liver fibrosis. Chin J Dig 2000; 20(4): 258–260.
Olaso E, Friedman SL. Molecular regulation of hepatic fibrogenesis. J Hepatol 1998; 29(5): 836–847
Friedman SL. Cytokines and fibrogenesis. Semin Liver Dis 1999;19(2): 129–140.
Williams EJ, Iredale JP. Liver cirrhosis. Postgrad Med J 1998; 74(870): 193–202.
Wu J, Zern MA. Hepatic stellate cells: a target for the treatment of liver fibrosis. J Gastroenterol 2000; 35(9): 665–672.
Wu YY, Cheng ML, Lu T, et al. Effect of Handan Ganle on the proliferation of fat-storing cell of mouse liver. Guizhou Med J 2000; 24(1): 15–16.
0
Views
417
Downloads
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010802024621